View ValuationZIVO Bioscience 향후 성장Future 기준 점검 2/6ZIVO Bioscience은 연간 수입과 매출이 각각 7.2%와 112.2% 증가할 것으로 예상되고 EPS는 연간 41.3%만큼 증가할 것으로 예상됩니다.핵심 정보7.2%이익 성장률41.26%EPS 성장률Personal Products 이익 성장8.5%매출 성장률112.2%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트16 Nov 2023최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 07University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryZIVO Bioscience, Inc. announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Building upon the outcomes of the initial study, this second study aimed to assess and compare the performance of three different ZIVO formulations in both directly challenged and contact-exposed birds. The study affirmed earlier observations that ZIVO's active ingredients may positively influence LPAI transmission dynamics, while identifying the optimal formulation for further testing. In the first arm of the study, which involved birds receiving a direct challenge with LPAI, modest positive trends were observed in viral shedding reduction among ZIVO-treated groups compared with untreated controls. While these differences did not reach statistical significance, the findings suggest potential for ZIVO's formulations to lessen disease severity. Notably, the formulation consisting of a blend of four distinct algal-derived materials demonstrated a slower and less efficient spread of the virus. One bird treated with this combination showed no signs of infection post-exposure, indicating potential protective effects. These findings resulting from rigorous testing at the University of Delaware reinforce commitment to developing sustainable, non-antibiotic solutions for the poultry industry. The insights gained from this study show encouraging trends and identifying a superior formulation will be instrumental in guiding future research and product optimization efforts. Given the potential impact ZIVO's product can have on mitigating Avian influenza, a widespread issue in the nation's large poultry industry, the company submitted a funding request to the State of Michigan for $5.5 million to further research. Additionally, the company are applying for a portion of the previously announced $100 million Avian Influenza Poultry Innovation Grand Challenge from the USDA.공시 • Apr 28ZIVO Bioscience, Inc., Annual General Meeting, Jun 09, 2025ZIVO Bioscience, Inc., Annual General Meeting, Jun 09, 2025. Location: 2125 butterfield road, suite 100, mi 48084, troy, United States공시 • Dec 21ZIVO Bioscience, Inc. Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian InfluenzaZivo Bioscience, Inc. reported favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO's proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Key findings of statistical significance from the study include: A reduction in viral titers (viral shedding) in infected birds receiving ZIVO's products compared with untreated infected controls. A delay in transmission of LPAI when healthy birds were exposed to infected birds, suggesting a slower and less aggressive spread of disease. The two-part controlled study evaluated the efficacy of ZIVO's proprietary Active ingredients, previously shown to be efficacious for mitigating the effects of coccidiosis in broiler chickens, against LPAI. In the second part, healthy chickens were housed with infected birds, replicating a real-world, high-risk environment for disease transmission. Compared to an untreated control group, birds that received ZIVO's proprietary active ingredient that were housed with infected birds experienced a statistically significant delay in viral detection. This observed delay suggests that ZIVO's products limit viral replication within a host. These favorable results indicate that ZIVO's proprietary active Ingredients represent potential preventative measures for reducing the spread of LPAIV in commercial poultry operations and enhancing overall flock health. Multiple products were explored to identify the most effective strategies against LPAI. While some products were better at lowering the viral titer, others were more effective at slowing the spread, suggesting that an optimal product configuration could provide more comprehensive protection. The study's positive outcomes justify further research and product development, supporting the potential of ZIVO' pipeline to address both LPAIV infections as well as a broad spectrum of other viral challenges faced by the poultry industry. "The University of Delaware's findings provide compelling evidence that its feed ingredients could be valuable tools in mitigating the risk of avian influenza outbreaks without the limitations associated with vaccines. Reducing disease transmission can positively impact both animal welfare and the operations of producers. These study results represent a significant milestone in efforts to deliver science-driven, sustainable solutions to address serious challenges facing the global poultry industry".공시 • Aug 23ZIVO Bioscience, Inc. Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler ChickensZIVO Bioscience, Inc. reported favorable results from its latest 42-day study with its product targeting coccidiosis in broiler chickens. The study, which was conducted in collaboration with a major global animal health company and replicated real-world poultry production environments, further validates the efficacy of ZIVO’s non-antibiotic, immune-modulating product designed for the treatment of coccidiosis. Funded by the major animal health company, the study focused on the overall health and productivity of birds challenged with the coccidiosis-causing parasite, Eimeria, while comparing administration of ZIVO’s product alone or in combination with either an ionophore-based treatment or a coccidiosis vaccine versus birds treated with the ionophore or vaccination alone. Uninfected/untreated healthy birds and infected/untreated birds served as negative and positive disease controls, respectively. In this study, broiler chickens infected with coccidiosis and treated with ZIVO’s product in combination with an anticoccidial ionophore or vaccination exhibited statistically significant improvements in both growth performance (as measured by feed conversion ratio, FCR) and clinical signs of disease (as measured by intestinal lesion scores), compared with chickens that received only the ionophore or vaccine. With respect to FCR over the 42-day grow-out period, groups treated with ZIVO’s product in combination with either the ionophore or vaccination performed on par with the healthy, uninfected control group.공시 • Apr 28ZIVO Bioscience, Inc., Annual General Meeting, Jun 11, 2024ZIVO Bioscience, Inc., Annual General Meeting, Jun 11, 2024, at 10:00 US Eastern Standard Time. Location: 3600 Centerpoint Parkway Pontiac United States Agenda: To consider and approve the appointment of independent registered public accounting firm for the fiscal year ending December 31, 2024; to consider and approve the compensation of executive officers; and to consider and approve any other matters.공시 • Feb 16+ 1 more updateThe Nasdaq Stock Market to Delist the Common Stock of ZIVO BioscienceThe Nasdaq Stock Market announced on February 13, 2024, that it will delist the common stock and warrants of Zivo Bioscience, Inc. Zivo Bioscience's securities were suspended on November 27, 2023, and have not traded on Nasdaq since that time.공시 • Feb 08ZIVO Bioscience, Inc. Reports Additional Findings from Positive 42-Day Coccidiosis Challenge StudyZivo Bioscience, Inc. announced additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics. ZIVO’s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. These new results, along with earlier findings, further demonstrate the benefits of ZIVO’s product across the broiler production value chain. ZIVO previously reported the effects of its product on the health of broiler chickens exposed to coccidiosis during the course of a 42-day grow out period, which is typical for the poultry industry. These health benefits included a statistically significant reduction in intestinal damage caused by the Eimeria parasite compared with untreated control birds. This improvement in intestinal health following parasite exposure was on par with the market-leading commercial ionophore. ZIVO now reports that this reduction in intestinal damage enables poultry farms to optimize feed utilization as measured by the Feed Conversion Ratio (FCR), which is the primary driver of profitability. Similar to the outcomes related to intestinal damage, ZIVO’s product resulted in a statistically significant improvement in FCR compared with untreated controls. Further, these results were not statistically different from the market-leading commercial ionophore.공시 • Jan 23Zivo Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler ChickensZivo Bioscience, Inc. announced positive efficacy results following its recent 42-day coccidiosis challenge study further demonstrating the effectiveness of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO’s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. With these and earlier test results, ZIVO will pursue a partnership with a global animal health company for commercializing its coccidiosis product. The study design was similar to that of a previously successful 28-day challenge study but was extended through 42 days to replicate real-world conditions of the broiler production industry. The results of the study in which the ZIVO treatment groups and a placebo control were blinded to the independent study contractor confirm previously reported positive effects of ZIVO’s non-antibiotic alternative for maintaining broiler health against coccidiosis. Notably, the study also showed that the performance of ZIVO’s product candidate was comparable to that of a market leading anticoccidial product.공시 • Jan 18ZIVO Bioscience, Inc. announced that it has received $0.531142 million in fundingOn January 16, 2024, ZIVO Bioscience, Inc. closed the transaction.공시 • Nov 29Nasdaq Determines to Delist the ZIVO Bioscience's Common Stock from the Nasdaq Capital MarketOn November 22, 2023, the ZIVO Bioscience, Inc. was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that as a result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist the Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock effective at the open of business, on November 27, 2023. Nasdaq further indicated that it will file a Form 25 Notification of Delisting with the Securities and Exchange Commission (the “SEC”). The Company has applied to have its common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OTC Markets Group Inc. for eligible securities traded over-the-counter. Pending approval, the Company expects that trading of the Company’s common stock will commence on the OTC Pink Sheets at the open of business on November 27, 2023. The transition to the quotation of the Company’s common stock on the OTC Markets will have no effect on the Company’s business or operations.이익 및 매출 성장 예측MUN:9R80 - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20252-7N/AN/A112/31/20242-7N/AN/A112/31/20230-8N/AN/A19/30/20230-9-7-7N/A6/30/20230-9-6-6N/A3/31/2023N/A-9-6-6N/A12/31/2022N/A-9-7-7N/A9/30/2022N/A-9-8-8N/A6/30/2022N/A-9-8-8N/A3/31/2022N/A-9-9-9N/A12/31/2021N/A-9-7-7N/A9/30/2021N/A-7-6-6N/A6/30/2021N/A-9-5-5N/A3/31/2021N/A-9-3-3N/A12/31/20200-9-3-3N/A9/30/20200-11-2-2N/A6/30/20200-10-3-3N/A3/31/20200-11-4-4N/A12/31/2019N/A-12-4-4N/A9/30/2019N/A-10-4-4N/A6/30/2019N/A-13-4-4N/A3/31/2019N/A-14-5-5N/A12/31/2018N/A-15-5-5N/A9/30/2018N/A-15-5-5N/A6/30/2018N/A-14-5-5N/A3/31/2018N/A-12-5-5N/A12/31/2017N/A-10-4-4N/A9/30/2017N/A-7-4-4N/A6/30/2017N/A-6N/A-3N/A3/31/2017N/A-7N/A-2N/A12/31/2016N/A-6N/A-3N/A9/30/2016N/A-6N/A-2N/A6/30/2016N/A-6N/A-2N/A3/31/2016N/A-6N/A-3N/A12/31/2015N/A-6N/A-2N/A9/30/2015N/A-4N/A-2N/A6/30/2015N/A-6N/A-3N/A3/31/2015N/A-5N/A-2N/A12/31/2014N/A1N/A-3N/A9/30/2014N/A0N/A-3N/A6/30/2014N/A-1N/A-3N/A3/31/2014N/A-5N/A-3N/A12/31/2013N/A-10N/A-3N/A9/30/2013N/A-11N/A-3N/A6/30/2013N/A-7N/A-2N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 9R80 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: 9R80 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: 9R80 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: 9R80 의 수익(연간 112.2%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 9R80 의 수익(연간 112.2%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 9R80의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHousehold 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/01/23 01:01종가2023/10/26 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ZIVO Bioscience, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Anthony VendettiMaxim Group
공시 • May 07University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryZIVO Bioscience, Inc. announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Building upon the outcomes of the initial study, this second study aimed to assess and compare the performance of three different ZIVO formulations in both directly challenged and contact-exposed birds. The study affirmed earlier observations that ZIVO's active ingredients may positively influence LPAI transmission dynamics, while identifying the optimal formulation for further testing. In the first arm of the study, which involved birds receiving a direct challenge with LPAI, modest positive trends were observed in viral shedding reduction among ZIVO-treated groups compared with untreated controls. While these differences did not reach statistical significance, the findings suggest potential for ZIVO's formulations to lessen disease severity. Notably, the formulation consisting of a blend of four distinct algal-derived materials demonstrated a slower and less efficient spread of the virus. One bird treated with this combination showed no signs of infection post-exposure, indicating potential protective effects. These findings resulting from rigorous testing at the University of Delaware reinforce commitment to developing sustainable, non-antibiotic solutions for the poultry industry. The insights gained from this study show encouraging trends and identifying a superior formulation will be instrumental in guiding future research and product optimization efforts. Given the potential impact ZIVO's product can have on mitigating Avian influenza, a widespread issue in the nation's large poultry industry, the company submitted a funding request to the State of Michigan for $5.5 million to further research. Additionally, the company are applying for a portion of the previously announced $100 million Avian Influenza Poultry Innovation Grand Challenge from the USDA.
공시 • Apr 28ZIVO Bioscience, Inc., Annual General Meeting, Jun 09, 2025ZIVO Bioscience, Inc., Annual General Meeting, Jun 09, 2025. Location: 2125 butterfield road, suite 100, mi 48084, troy, United States
공시 • Dec 21ZIVO Bioscience, Inc. Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian InfluenzaZivo Bioscience, Inc. reported favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO's proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Key findings of statistical significance from the study include: A reduction in viral titers (viral shedding) in infected birds receiving ZIVO's products compared with untreated infected controls. A delay in transmission of LPAI when healthy birds were exposed to infected birds, suggesting a slower and less aggressive spread of disease. The two-part controlled study evaluated the efficacy of ZIVO's proprietary Active ingredients, previously shown to be efficacious for mitigating the effects of coccidiosis in broiler chickens, against LPAI. In the second part, healthy chickens were housed with infected birds, replicating a real-world, high-risk environment for disease transmission. Compared to an untreated control group, birds that received ZIVO's proprietary active ingredient that were housed with infected birds experienced a statistically significant delay in viral detection. This observed delay suggests that ZIVO's products limit viral replication within a host. These favorable results indicate that ZIVO's proprietary active Ingredients represent potential preventative measures for reducing the spread of LPAIV in commercial poultry operations and enhancing overall flock health. Multiple products were explored to identify the most effective strategies against LPAI. While some products were better at lowering the viral titer, others were more effective at slowing the spread, suggesting that an optimal product configuration could provide more comprehensive protection. The study's positive outcomes justify further research and product development, supporting the potential of ZIVO' pipeline to address both LPAIV infections as well as a broad spectrum of other viral challenges faced by the poultry industry. "The University of Delaware's findings provide compelling evidence that its feed ingredients could be valuable tools in mitigating the risk of avian influenza outbreaks without the limitations associated with vaccines. Reducing disease transmission can positively impact both animal welfare and the operations of producers. These study results represent a significant milestone in efforts to deliver science-driven, sustainable solutions to address serious challenges facing the global poultry industry".
공시 • Aug 23ZIVO Bioscience, Inc. Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler ChickensZIVO Bioscience, Inc. reported favorable results from its latest 42-day study with its product targeting coccidiosis in broiler chickens. The study, which was conducted in collaboration with a major global animal health company and replicated real-world poultry production environments, further validates the efficacy of ZIVO’s non-antibiotic, immune-modulating product designed for the treatment of coccidiosis. Funded by the major animal health company, the study focused on the overall health and productivity of birds challenged with the coccidiosis-causing parasite, Eimeria, while comparing administration of ZIVO’s product alone or in combination with either an ionophore-based treatment or a coccidiosis vaccine versus birds treated with the ionophore or vaccination alone. Uninfected/untreated healthy birds and infected/untreated birds served as negative and positive disease controls, respectively. In this study, broiler chickens infected with coccidiosis and treated with ZIVO’s product in combination with an anticoccidial ionophore or vaccination exhibited statistically significant improvements in both growth performance (as measured by feed conversion ratio, FCR) and clinical signs of disease (as measured by intestinal lesion scores), compared with chickens that received only the ionophore or vaccine. With respect to FCR over the 42-day grow-out period, groups treated with ZIVO’s product in combination with either the ionophore or vaccination performed on par with the healthy, uninfected control group.
공시 • Apr 28ZIVO Bioscience, Inc., Annual General Meeting, Jun 11, 2024ZIVO Bioscience, Inc., Annual General Meeting, Jun 11, 2024, at 10:00 US Eastern Standard Time. Location: 3600 Centerpoint Parkway Pontiac United States Agenda: To consider and approve the appointment of independent registered public accounting firm for the fiscal year ending December 31, 2024; to consider and approve the compensation of executive officers; and to consider and approve any other matters.
공시 • Feb 16+ 1 more updateThe Nasdaq Stock Market to Delist the Common Stock of ZIVO BioscienceThe Nasdaq Stock Market announced on February 13, 2024, that it will delist the common stock and warrants of Zivo Bioscience, Inc. Zivo Bioscience's securities were suspended on November 27, 2023, and have not traded on Nasdaq since that time.
공시 • Feb 08ZIVO Bioscience, Inc. Reports Additional Findings from Positive 42-Day Coccidiosis Challenge StudyZivo Bioscience, Inc. announced additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics. ZIVO’s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. These new results, along with earlier findings, further demonstrate the benefits of ZIVO’s product across the broiler production value chain. ZIVO previously reported the effects of its product on the health of broiler chickens exposed to coccidiosis during the course of a 42-day grow out period, which is typical for the poultry industry. These health benefits included a statistically significant reduction in intestinal damage caused by the Eimeria parasite compared with untreated control birds. This improvement in intestinal health following parasite exposure was on par with the market-leading commercial ionophore. ZIVO now reports that this reduction in intestinal damage enables poultry farms to optimize feed utilization as measured by the Feed Conversion Ratio (FCR), which is the primary driver of profitability. Similar to the outcomes related to intestinal damage, ZIVO’s product resulted in a statistically significant improvement in FCR compared with untreated controls. Further, these results were not statistically different from the market-leading commercial ionophore.
공시 • Jan 23Zivo Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler ChickensZivo Bioscience, Inc. announced positive efficacy results following its recent 42-day coccidiosis challenge study further demonstrating the effectiveness of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO’s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. With these and earlier test results, ZIVO will pursue a partnership with a global animal health company for commercializing its coccidiosis product. The study design was similar to that of a previously successful 28-day challenge study but was extended through 42 days to replicate real-world conditions of the broiler production industry. The results of the study in which the ZIVO treatment groups and a placebo control were blinded to the independent study contractor confirm previously reported positive effects of ZIVO’s non-antibiotic alternative for maintaining broiler health against coccidiosis. Notably, the study also showed that the performance of ZIVO’s product candidate was comparable to that of a market leading anticoccidial product.
공시 • Jan 18ZIVO Bioscience, Inc. announced that it has received $0.531142 million in fundingOn January 16, 2024, ZIVO Bioscience, Inc. closed the transaction.
공시 • Nov 29Nasdaq Determines to Delist the ZIVO Bioscience's Common Stock from the Nasdaq Capital MarketOn November 22, 2023, the ZIVO Bioscience, Inc. was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that as a result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist the Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock effective at the open of business, on November 27, 2023. Nasdaq further indicated that it will file a Form 25 Notification of Delisting with the Securities and Exchange Commission (the “SEC”). The Company has applied to have its common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OTC Markets Group Inc. for eligible securities traded over-the-counter. Pending approval, the Company expects that trading of the Company’s common stock will commence on the OTC Pink Sheets at the open of business on November 27, 2023. The transition to the quotation of the Company’s common stock on the OTC Markets will have no effect on the Company’s business or operations.